Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) has been identified as one of the most promising low-cost stocks to buy now. Bank of America raised Syndax’s price target to $28 and maintained a Buy rating. The company recently partnered with the World Orphan Drug Alliance to launch a Managed Access Program for Revuforj, its menin inhibitor. This program will allow physicians to prescribe the medication in regions where it is not yet commercially available. In the US, Revuforj is already FDA-approved for certain types of leukemia.

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is a biopharmaceutical company focused on cancer treatment. While SNDX shows potential as an investment, other AI stocks may offer greater upside potential. Investors seeking an undervalued AI stock should consider options that could benefit from current economic trends. Check out reports on the best short-term AI stocks, stocks expected to double in 3 years, and hidden AI stocks. Note: This article was originally published on Insider Monkey.

Read more at Yahoo Finance: BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact